BSEOthersExpansion3h ago
Godavari Drugs Ltd
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we inform that the Board of Directors at its meeting held on 31st August, 2026 approved the following:
1. Alteration of the ....
Godavari Drugs Ltd has announced that its Board of Directors has approved the alteration of the Main Objects Clause III(A) of the Memorandum of Association to include the business of nutraceuticals, dietary supplements, natural extracts, food ingredients, and allied products. The company also revised the notice convening the 38th Annual General Meeting to be held on September 25, 2026.
BSECompany Update17 Aug 2026
Godavari Drugs Ltd
Submission of Statement on Deviation or Variation in uitilisation of Funds for the quarter ended 30 june 2026
Godavari Drugs Ltd has submitted a statement on deviation or variation in utilization of funds for the quarter ended 30 June 2026, as per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BSECompany UpdateResults17 Aug 2026
Godavari Drugs Ltd
Newspaper Publication of Unaudited Results for quarter ended 30.06.2026
Godavari Drugs Ltd has published unaudited financial results for the quarter ended June 30, 2026, in accordance with SEBI regulations.
BSECompany UpdateFundraise14 Aug 2026
Godavari Drugs Ltd
Board of Directors of the Company in its meeting held on Friday, 14th August, 2026 at 11.45 A.M. approved and passed the resolution for allotment of Equity Shares on conversion of 7,86,690 ....
Godavari Drugs Ltd has announced the allotment of 7,86,690 equity shares on conversion of warrants to promoters at an issue price of Rs. 89/- each, increasing the paid-up equity capital from Rs. 10,12,74,350/- to Rs. 10,91,41,250/-.
BSEResultResults14 Aug 2026
Godavari Drugs Ltd
Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026
Godavari Drugs Ltd has submitted its un-audited standalone financial results for the quarter ended June 30, 2026, showing a net profit of Rs. 110.91 crores.
BSEBoard MeetingResults14 Aug 2026
Godavari Drugs Ltd
Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026 and Allotment of Equity Shares on conversion of 7,86,690 (Seven Lakhs Eighty-Six Thousand ....
Godavari Drugs Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, and has also allotted 7,86,690 equity shares on conversion of warrants to promoters at Rs. 89 per share.
BSEBoard MeetingResults11 Aug 2026
Godavari Drugs Ltd
Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Update on board meeting - Intimation ....
Godavari Drugs Ltd has issued a corrigendum to correct a typographical error in its earlier intimation letter regarding the Board Meeting scheduled on 14/08/2026 to consider and approve the Un-Audited Financial Results for the first quarter ended 30/06/2026.
BSEBoard MeetingResults10 Aug 2026
Godavari Drugs Ltd
Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....
Godavari Drugs Ltd has scheduled a Board Meeting on August 14, 2026, to consider and approve the Un-audited Financial Results for the quarter ended June 30, 2026, along with a Limited review report.
BSEInsider Trading / SAST23 Jun 2026
Godavari Drugs Ltd
Intimation of Closure of Trading window for the quarter ended June 30, 2026
Godavari Drugs Ltd has announced the closure of its trading window for Designated Persons and their immediate relatives from July 1, 2026, until 48 hours after the declaration of un-audited financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent insider trading ahead of financial disclosures.